Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,...

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in...

Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

CloudMedx Working With UCSF to Deploy AI Tools to Support the Management of Liver Cancer Patients Awaiting Liver Transplant PALO ALTO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced it is working with...